Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has
received commitments from institutional investors to purchase
approximately $32.9 million of its securities pursuant to an effective
shelf registration statement.
Under the terms of one of two types of purchase agreements, Optimer will
sell 2,794,700 newly issued shares of its common stock at a purchase
price of $10.00 per share. In the other purchase agreement Optimer will
sell 457,666 newly issued units at a purchase price of $10.925 per unit,
with each unit consisting of one share of common stock and one warrant
to purchase 0.20 of a share of common stock. The warrants are
exercisable six months after the date of issuance at $10.93 per share
and will expire five years from the date of issuance.
The closing of this offering is expected to take place on March 9, 2009.
Proceeds from the transaction will be used in the further development of
Optimer’s ongoing programs, as well as for other general corporate
purposes.
Copies of the final prospectus supplement and accompanying base
prospectus can be obtained from the Corporate Communications Manager,
Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Road, Suite C, San
Diego, CA 92121.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor will there be any sale of these
securities in any state in which to offer, solicitation or sale would be
unlawful prior to registration statement or qualification under the
securities laws of any such state.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative anti-infective
products to treat serious infections and address unmet medical needs.
Optimer has two late-stage anti-infective product candidates under
development. Fidaxomicin, formerly known as OPT-80, is the only
antibiotic therapy currently in Phase 3 worldwide clinical development
for Clostridium difficile infection. Prulifloxacin is an
antibiotic which has completed two Phase 3 clinical trials for the
treatment of travelers’ diarrhea, a form of infectious diarrhea.
Additional information can be found at http://www.optimerpharma.com.
Forward-looking Statements
Statements included in this press release that are not a description of
historical facts are forward-looking statements, including without
limitation all statements related to the expected closing of the
offering and Optimer’s receipt and use of the offering proceeds. Words
such as "believes," "anticipates," "plans," "expects," "intend," "will,"
"goal" and similar expressions are intended to identify forward-looking
statements. The inclusion of forward-looking statements should not be
regarded as a representation by Optimer that any of its plans will be
achieved. Actual results may differ materially from those set forth in
this release due to the risks and uncertainties inherent in Optimer's
business including, without limitation, risks relating to: whether the
investors will fulfill their obligations to purchase the securities in
the offering, whether Optimer will be able to satisfy its closing
conditions set forth in the purchase agreements and other risks detailed
in Optimer's filings with the Securities and Exchange Commission.
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate
Communications Manager
John D. Prunty, Chief Financial Officer & VP
Finance
858-909-0736
or
Porter Novelli Life Sciences
Jason
I. Spark, Vice President
619-849-6005
